Artemisinin inhibits neuroblastoma proliferation through activation of AHP-activated protein kinase (AMPK) signaling

Pharmazie

Volumn 69, Issue 6, 2014, Pages 468-472

  Tan, Wei Qiang ^a   Chen, Gang ^a   Jia, Bing ^a   Ye, Ming ^a  

^a CHILDREN S HOSPITAL OF FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE KINASE; ARTEMISININ; PROTEIN KINASE;

ARTICLE; CELL CYCLE REGULATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; NEUROBLASTOMA; SIGNAL TRANSDUCTION;

ANIMALS; ANTIMALARIALS; ANTIMETABOLITES; ANTINEOPLASTIC AGENTS; ARTEMISININS; BLOTTING, WESTERN; BRAIN NEOPLASMS; BROMODEOXYURIDINE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; NEUROBLASTOMA; REAL-TIME POLYMERASE CHAIN REACTION; RNA; RNA, SMALL INTERFERING;

EID: 84903272387     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2014.3779     Document Type: Article

References (20)

1. Alcantara DD, Ribeiro HF, Cardoso PC, Araujo TM, Burbano RR, Guimaraes AC, Khayat AS, de Oliveira BM (2013) In vitro evaluation of the cytotoxic and genotoxic effects of artemether, an antimalarial drug, in a gastric cancer cell line (PG100). J Appl Toxicol 33: 151-156.
2. Ali R, Mirza Z, Ashraf GM, Kamal MA, Ansari SA, Damanhouri GA, Abuzenadah AM, Chaudhary AG, Sheikh IA (2012) New anticancer agents: recent developments in tumor therapy. Anticancer Res 32: 2999-3005.
3. Berkovich L, Ron I, Earon G, Abu-Ghanem S, Rimmon A, Lev-Ari S (2012) [The role of medicinal herbs with anti-inflammatory properties in prevention and treatment of cancer]. Harefuah 151: 629-632, 654.
4. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, Viollet B, Thompson CB (2007) Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 67: 6745-6752. (Pubitemid 47105521)
5. Efferth T, Dunstan H, Sauerbrey A, Miyachi H, Chitambar CR (2001) The anti-malarial artesunate is also active against cancer. Int J Oncol 18: 767-773.
6. Gong Y, Gallis BM, Goodlett DR, Yang Y, Lu H, Lacoste E, Lai H, Sasaki T (2013) Effects of transferrin conjugates of artemisinin and artemisinin dimer on breast cancer cell lines. Anticancer Res 33: 123-132.
7. Gordi T, Lepist EI (2004) Artemisinin derivatives: toxic for laboratory animals, safe for humans? Toxicol Lett 147: 99-107. (Pubitemid 38130178)
8. Hardie DG (2007) AMP-activated protein kinase as a drug target. Ann Rev Pharmacol Toxicol 47: 185-210.
9. Kim HS, Kim MJ, Kim EJ, Yang Y, Lee MS, Lim JS (2012) Berberine-induced AMPK activation inhibits the metastatic potential of melanoma cells via reduction of ERK activity and COX-2 protein expression. Biochem Pharmacol 83: 385-394.
10. McLeod HL (2013) Cancer pharmacogenomics: early promise, but concerted effort needed. Science 339: 1563-1566.
11. Park YJ, Ko JW, Jang Y, Kwon YH (2013) Activation of AMP-activated protein kinase alleviates homocysteine-mediated neurotoxicity in SH-SY5Y cells. Neurochem Res 38: 1561-1571.
12. Pietras W (2012) Advances and changes in the treatment of children with nephroblastoma. Adv Clin Exp Med 21: 809-820.
13. Reungpatthanaphong P and Mankhetkorn S (2002) Modulation of multidrug resistance by artemisinin, artesunate and dihydroartemisinin in K562/adr and GLC4/adr resistant cell lines. Biol Pharm Bull 25: 1555-1561. (Pubitemid 39663669)
14. Riganti C, Doublier S, Viarisio D, Miraglia E, Pescarmona G, Ghigo D, Bosia A (2009) Artemisinin induces doxorubicin resistance in human colon cancer cells via calcium-dependent activation of HIF-1alpha and P-glycoprotein overexpression. Br J Pharmacol 156: 1054-1066.
15. Shackelford DB, Shaw RJ (2009) The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer 9: 563-575.
16. Singh NP, Lai HC, Park JS, Gerhardt TE, Kim BJ, Wang S, Sasaki T (2011) Effects of artemisinin dimers on rat breast cancer cells in vitro and in vivo. Anticancer Res 31: 4111-4114.
17. Swinnen JV, Beckers A, Brusselmans K, Organe S, Segers J, Timmermans L, Vanderhoydonc F, Deboel L, Derua R, Waelkens E, De Schrijver E, Van de Sande T, Noel A, Foufelle F, Verhoeven G (2005) Mimicry of a cellular low energy status blocks tumor cell anabolism and suppresses the malignant phenotype. Cancer Res 65: 2441-2448. (Pubitemid 40490156)
18. Tin AS, Sundar SN, Tran KQ, Park AH, Poindexter KM, Firestone GL (2012) Antiproliferative effects of artemisinin on human breast cancer cells requires the downregulated expression of the E2F1 transcription factor and loss of E2F1-target cell cycle genes. Anticancer Drugs 23: 370-379.
19. Tonini GP, Nakagawara A, Berthold F (2012) Towards a turning point of neuroblastoma therapy. Cancer Lett 326: 128-134.
20. Zhou C, Pan W, Wang XP, Chen TS (2012) Artesunate induces apoptosis via a Bak-mediated caspase-independent intrinsic pathway in human lung adenocarcinoma cells. J Cell Physiol 227: 3778-3786.